ABOUT US
Introduction
Chairman's Statement
Contact Us
R&D
R&D Platforms
R&D Capability
R&D Center
PRODUCTS
bFGF Series
other ophthalmic products
other surgical products
NEWS
company news
investee news
media focus
INVESTOR RELATIONS
Announcements & Shareholder Info
Corporate Info
Financial & ESG Reports
Contact Us
CAREERS
Talent Concept
Job Opportunities
简
繁
EN
ABOUT US
Introduction
Chairman's Statement
Contact Us
R&D
R&D Platforms
R&D Capability
R&D Center
PRODUCTS
bFGF Series
other ophthalmic products
other surgical products
NEWS
company news
investee news
media focus
INVESTOR RELATIONS
Announcements & Shareholder Info
Corporate Info
Financial & ESG Reports
Contact Us
CAREERS
Talent Concept
Job Opportunities
简
繁
EN
简
繁
EN
COMPANY NEWS
Essex Bio-Technology and Mitotech Complete Enrollment in VISTA-2 – a Pivotal Phase 3 Clinical Study of SkQ1 for Dry Eye Disease
2020.08.25
Time
Last 7 days
Last 30 days
The last six months
Date
Title
2020-08-25
Essex Bio-Technology and Mitotech Complete Enrollment in VISTA-2 – a Pivotal Phase 3 Clinical Study of SkQ1 for Dry Eye Disease
2020-08-18
Essex Bio-Technology Reports First Half 2020 Financial Results
2020-08-10
Essex Bio-Technology Enters into Global Out-licence Agreement with Kelun-Biotech
2020-04-30
Essex Bio-Technology Joins X-ZELL Seed+ Investment Round
2020-03-17
FY 2019 Profit-After-Tax Up 30.9% to HK$302.5 million,was up 36.5% in RMB denomination
2019-12-27
Preservative-free Single-dose rb-bFGF Eye Drops (Single-Dose Beifushu Eye Drops) Obtained Approval from NMPA for Commercialisation in China
2019-12-12
Essex Bio-Technology and Mitotech Announce First Patient First Visit in U.S. FDA Second Phase 3 Clinical Trial of SkQ1
2019-08-21
Admission of Product to the PRC National Drug List for Reimbursement, Beifuxin Newly Listed and the Other Three Products Remain on the List
<
1
2
3
4
>
